Positive impactSector
Kotak adds 5 new midcap stocks which fell up to 16% in one month to its model portfolio. Take a look
Economic Times 1 hr ago·28 Oct 2026, 4:07 am
Kotak Institutional Equities has expanded its model portfolio by adding five midcap stocks that have recently faced significant declines. This strategic move signals that the brokerage firm sees value in these companies despite the broader market volatility. The additions include Aster DM Quality Care, Dixon Tech, Emcure Pharmaceuticals, and Endurance Technologies, among others.
For investors, this development is noteworthy as it highlights specific names that the brokerage believes are currently undervalued. By including these stocks, Kotak is indicating a belief in their potential for recovery and growth. This could be a signal for retail investors to pay closer attention to these specific midcap names as they navigate the current market environment.
Moving forward, investors should monitor the performance of these newly added stocks. It is crucial to watch for any signs of stabilization in their share prices and the overall market sentiment towards midcap equities. Keeping an eye on the quarterly earnings and business outlook of these companies will be key to understanding their future trajectory.
Excerpt from Economic Times
Kotak Institutional Equities in its latest Strategy report announced some changes to its model portfolio. It said the favorable price-value gap in more stocks after the sharp correction in recent weeks will help dispel the ‘gloomy’ mood in the market. The brokerage replaced Bajaj Finserv with Bajaj Finance in the…Read the original at Economic Times
Affected stocks
Bullish4 stocks
Emcure Pharmaceuticals
EMCURE Bullish
₹1,875.20
ENDURANCE
ENDURANCE Bullish
—
ASTERDM
ASTERDM Bullish
—
DIXON
DIXON Bullish
—
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Emcure Pharmaceuticals (EMCURE).
- Category: Sector.
- AI reads the tone as positive (potentially bullish) for the stock.
- Also mentions ENDURANCE, ASTERDM, DIXON.
Why it matters
A routine update for Emcure Pharmaceuticals. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
